Tolerability of 1% tapinarof cream in adults and children with atopic dermatitis

Summaries 1 min 163

Font Size

Created On: 05/06/2025

Tapinarof cream 1% once daily (QD) has shown robust efficiency in individuals as young as 2 years with atopic dermatitis (AD) in the phase 3 ADORING 1 and 2 trials. This study presented findings on its local tolerability profile.

See All

Key take away

In adults and children with atopic dermatitis, once daily use of 1% tapinarof cream is well-tolerated, even on sensitive skin areas.

Background

Method

Volunteers were randomized to get either tapinarof or vehicle cream QD over an 8-week treatment period. Local tolerability was assessed via standardized 5-point Local Tolerability Scales (LTS), completed by patients, caregivers, and investigators. Particular attention was given to sensitive skin regions, including the neck and face.

Result

In total, 813 patients were enrolled, with pediatrics comprising about 80% of the cohort. Baseline mean LTS scores indicated mild symptoms across groups—1.0–1.9 (patient-reported) for burning/stinging and itching, and 0.3–0.6 (investigator-reported) for peeling, erythema, and dryness.

Over the course of treatment, tapinarof illustrated favorable tolerability, with mean week 8 patient-reported LTS scores declining to 0.6–0.8 for itching and 0.2–0.4 for burning/stinging. Investigator assessments mirrored this betterment, with final scores of 0.2 and 0.1 in ADORING 1 and 2, respectively. In sensitive skin areas, irritation remained minimal throughout, with mean scores ranging from 0 to 0.3 for tapinarof and 0 to 1.0 for vehicle.

Conclusion

Tapinarof cream 1% QD exhibited a consistent and favorable local tolerability profile from initiation through week 8, including in sensitive skin regions. These findings support its suitability for long-term topical care of AD across age groups.